Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | BID | P55957 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.46 |
| ▸ | ACLY | P53396 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4121234 | 0.84 | CCR2 (0.72) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL31599460 | 0.84 | CCR2 (0.72) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL30220543 | 0.83 | CCR2 (0.54) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL24896255 | 0.83 | CCR2 (0.54) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL18537910 | 0.83 | NOD2 (0.67) | ALDH1A1LMNAMAPTHDAC3HDAC4 | |
| SCHEMBL18537908 | 0.83 | ALDH1A1 (0.42) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| Hydrochloric Acid SCHEMBL4119324 | 0.82 | CCR2 (0.71) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL708960 | 0.80 | HDAC3 (0.53) | CCR2ALDH1A1LMNAMAPTHDAC3 | |
| SCHEMBL17422830 | 0.80 | LMNA (0.42) | ALDH1A1LMNAMAPTHDAC3HDAC4 | |
| SCHEMBL17422763 | 0.80 | PPARG (0.44) | ALDH1A1LMNAMAPTACLYFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312493-A1 | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor | CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) | 2018-11-01 | — | — | US | disclosed |
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
| WO-2016004513-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312493-A1 | Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor | UGT1A8, CYP2C8, CXCL8 | CCR2 3596/4885ALDH1A1 803/4885LMNA 1975/4885 |
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | PDK1, PDK3, PDK2 | CCR2 3346/4885ALDH1A1 2424/4885LMNA 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.